[The toxicity of massive dosis of VM26 (4-demethyl-epipodophyllotoxin-beta-D-thenylidene glucoside). A contribution to the therapy of advanced ovarian cancer (author's transl)].
19 patients with advanced ovarian cancer (FIGO-stages IIb-IV) were treated by ultra-high doses of VM26 partly according to positive oncobiograms during Multiple-drug-stoss-therapy. The toxic reactions and the cytostatic effect were investigated. The range of 57,9% remissions and the moderate toxicity suggest a specific application of VM26 in advanced ovarian cancer.
D000368:Aged; D002986:Clinical Trials as Topic; D004341:Drug Evaluation; D005260:Female; D006801:Humans; D007970:Leukopenia / Q000139:chemically induced; D008875:Middle Aged; D009325:Nausea / Q000139:chemically induced; D010051:Ovarian Neoplasms / Q000188:drug therapy*; D011034:Podophyllotoxin / Q000031:analogs & derivatives*; D012075:Remission, Spontaneous; D013713:Teniposide / Q000008:administration & dosage / Q000009:adverse effects* / Q000627:therapeutic use; D014839:Vomiting / Q000139:chemically induced
D013713:Teniposide; D011034:Podophyllotoxin
Die Toxizität hoher Dosen von VM26 (4-demethyl-epipodophyllotoxin-beta-D-thenylidene glucoside). Ein Beitrag zur Behandlung des fortgeschrittenen Ovarialkarzinoms.